Several studies have retrospectively confirmed the role of WT1 as a MRD marker: a first one [46] analyzed 71 AML post-induction with a significant correlation between PB WT1 (>20/104 ABL copies) and the incidence of relapse (100% CIR in WT1+ patients, median time 7 months, vs. 43.7% in WT1− patients, median time 12 months). This evidence concerns the gene WT1 and acute myeloid leukemia.